VolitionRx Launches $7.5 Million At-the-Market Offering

Represented VolitionRx, a company which, through its subsidiaries, is developing and commercializing simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of diseases, including some cancers,diseases associated with NETosis and sepsis, with SEC effectiveness of a Shelf Registration Statement on Form S-3 and the launch of an At-the-Market Offering of up to $7.5 Million with JonesTrading Institutional Services LLC.